engleski

Initial Clinical Experience with Brinzolamide 1% ophtalmic suspension (Azopt)

The aim of the study was to assess the intraocular hypotensive effect of 1.0% brinzolamide (b.i.d.) as monotherapy in patients with primary and secondary glaucoma. The six-month study included 20 patients of which 19 completed the study. All patients had previously recived local antiglaucoma therapy. Because of local undesired side effects and inadequate control of intraocular pressure they were switched to treatment with brinzolamide as monotherapy.Intraocular pressure was measured on the day of therapy introduction, and then at 15 days, one month, three months and six months of therapy. Nineteen patients successfully completed the six months study. A clinically significant decrease in the intraocular pressure was recorded. The difference in intraocular pressure between the baseline (23.8+/-2.4), and 15-day (18.2+/-2.7), three-month(18.5+/-2.9) and six-month(18.8+/-3.2) levels was statistically significant(p<0.001). Deviation from the mean values of intraocular pressure was considered as tandard deviation. Local side effects such as scratching and pricking were recorded in three patients, however, there were no systemic or other side effects. Results of the study suggested monotherapy with 1.0%brinzolamide (b.i.d.) to be successful in the regulation of intraocular pressure in the patients with primary or secondary glaucoma.

Carbonic anhydrase inhibitors; therapeutic use; adverse effects; glaucoma; drug therapy

nije evidentirano